Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNS Uptake of Anti-CD8+ T Cell Minibodies in MS and PML
NCT05849467Phase 1Recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Oct 2023
- Primary completion
- Apr 2030
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of [89Zr]Zr-Df-Crefmirlimab in multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML) (3 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Infiltration of CD8+ T cells in the CNS at Day 1. Started Oct 2023; status: recruiting.
02
Drugs
[89Zr]Zr-Df-Crefmirlimab
03
Conditions
multiple sclerosis (MS)progressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on NCT05849467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849467.